Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Health
Biotech
First Opinion
The Readout

Sarepta investors have hope & Hillary moves the market

  • Damian Garde
  • Meghana Keshavan

By Damian Garde and Meghana Keshavan Aug. 25, 2016

Reprints
The READOUT
Alex Hogan/STAT

The Readout for August 25, 2016

About the Authors Reprints

Damian Garde

Damian Garde

National Biotech Reporter

Damian Garde covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast.

Meghana Keshavan

Meghana Keshavan

Biotech Correspondent

Meghana Keshavan covers biotech and contributes to The Readout newsletter.

Lab tests show risks of using CRISPR gene editing…
Lab tests show risks of using CRISPR gene editing on embryos
Working at the ‘top of my license’ means I…
Working at the ‘top of my license’ means I sometimes have to say no
Why you get paid to donate plasma but not…
Why you get paid to donate plasma but not blood
Regeneron targets obesity, a new microbiome deal, & comparing…
Regeneron targets obesity, a new microbiome deal, & comparing cancer drug costs
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries…
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries & regenerating heart tissue
Docs disagree with FDA on Aduhelm, Swiss giants pinch…
Docs disagree with FDA on Aduhelm, Swiss giants pinch pennies, & one SPAC makes it rain

Recommended Stories